Single domain antibodies have emerged as a new class of therapeutic molecules in antibody engineering. A single domain antibody (shark VNAR), in contrast to a conventional antibody (Fv), is capable of binding a buried functional site consisting of the enzyme’s substrate binding pocket. For additional information, see Ho, Searching for magic bullets, Antibody Therapeutics. DOI: https://doi.org/10.1093/abt/tby001.
Antibody Therapeutics, Volume 1, Issue 1, 20 June 2018, Pages 1–5, https://doi.org/10.1093/abt/tby001